Can the Expanded Disability Status Scale be assessed by telephone?Jeannette Lechner‐Scott, Robert Gibberd, Ludwig Kappos et al.|Multiple Sclerosis Journal|2003Cited by 143
NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosisSunny Malhotra, Manuel Comabella, Jordi Río et al.|Brain|2015Cited by 110
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Jeannette Lechner‐Scott et al.|JAMA Neurology|2023Cited by 62
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studiesJohanna Balslev Andersen, Gilles Edan, Sifat Sharmin et al.|Multiple Sclerosis and Related Disorders|2021Cited by 12
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Mathilde Lefort et al.|CNS Drugs|2021Cited by 12